Researchers in Alicante, Spain, established levels of normality for hemoglobin A in newborn screening by taking into account factors such as the babies being born prematurely and their mothers having immigrated from an area of the world where the prevalence of genetics mutations causing defects in the hemoglobin gene is high.
Özge Özkaya, PhD
Özge has a MSc. in Molecular Genetics from the University of Leicester and a PhD in Developmental Biology from Queen Mary University of London. She worked as a Post-doctoral Research Associate at the University of Leicester for six years in the field of Behavioural Neurology before moving into science communication. She worked as the Research Communication Officer at a London based charity for almost two years.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Özge Özkaya, PhD
Metformin, a common drug for type 2 diabetes could also be used to treat sickle cell anemia by increasing levels of fetal hemoglobin, found a study conducted by researchers at Baylor College of Medicine and Texas Children's Cancer and Hematology Centers.
Imara Announces First Person Dosed in Trial for IMR-687, Potential Therapy for Sickle Cell Anemia
Imara, a biotechnology company that is working towards developing new therapies against sickle cell anemia and other blood disorders, announced that the first healthy volunteer has been dosed in a Phase I clinical trial testing the safety and tolerability of their product candidate called IMR-687.